Toronto, Ontario--(Newsfile Corp. - August 7, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), an AI and data science company focused on preventative care, is pleased to announce the Company will release its Fiscal Second Quarter 2024 financial results for the period ended June 30, 2024, on Monday, August 12, 2024. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 5:30 pm EST (2:30 pm PST). The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Anthony Lam, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call.
Fiscal Second Quarter 2024 Conference Call
Date: Monday, August 12, 2024
Time: 5:30 PM ET / 2:30 PM PT
For attendees who wish to join by webcast, the event can be accessed at: https://edge.media-server.com/mmc/p/ejqqmqy4
Attendees who wish to join by phone must visit the following link and pre-register: https://register.vevent.com/register/BIa66ea4dcfe1b4dd981a3ee71ae03ad54
Instructions for joining by phone:
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI
About HEALWELL
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$1.50 |
Daily Change: | 0.10 7.14 |
Daily Volume: | 849,030 |
Market Cap: | C$204.500M |
September 25, 2024 August 22, 2024 July 31, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB